STOCK TITAN

[Form 4] Credo Technology Group Holding Ltd Insider Trading Activity

Filing Impact
(High)
Filing Sentiment
(Very Negative)
Form Type
4
Rhea-AI Filing Summary

Dyadic International (Nasdaq: DYAI) filed a Form 8-K on 23 Jul 2025 under Item 7.01 (Reg FD) to furnish an investor presentation titled “Precision engineered recombinant protein production that redefines performance, scalability and economy.” The deck, posted on the company’s website and attached as Exhibit 99.1, outlines a strategic shift from research-driven to commercially focused operations. Management plans to monetize its patented C1 and Dapibus™ gene-expression platforms by supplying high-value, non-therapeutic proteins to the life-science, food, nutrition and industrial bioprocessing markets. No new financial results, guidance, or transactional details were disclosed. Because the material is “furnished” rather than “filed,” it is not subject to Section 18 liability and will not be automatically incorporated into future Securities Act or Exchange Act filings. Exhibit 104 contains the inline XBRL cover page data.

Dyadic International (Nasdaq: DYAI) ha presentato un modulo 8-K il 23 luglio 2025 ai sensi dell'Elemento 7.01 (Reg FD) per fornire una presentazione agli investitori intitolata “Produzione di proteine ricombinanti di precisione che ridefinisce prestazioni, scalabilità ed economia.” La presentazione, pubblicata sul sito web dell'azienda e allegata come Exhibit 99.1, illustra un cambiamento strategico da un'operatività orientata alla ricerca a una focalizzata sul commerciale. Il management prevede di monetizzare le sue piattaforme brevettate di espressione genica C1 e Dapibus™ fornendo proteine non terapeutiche ad alto valore ai mercati delle scienze della vita, alimentare, nutrizionale e del bioprocesso industriale. Non sono stati divulgati nuovi risultati finanziari, previsioni o dettagli transazionali. Poiché il materiale è “fornito” e non “depositato,” non è soggetto alla responsabilità ai sensi della Sezione 18 e non sarà automaticamente incorporato nelle future dichiarazioni ai sensi del Securities Act o dell'Exchange Act. L'Exhibit 104 contiene i dati della pagina di copertina XBRL in linea.

Dyadic International (Nasdaq: DYAI) presentó un Formulario 8-K el 23 de julio de 2025 bajo el Ítem 7.01 (Reg FD) para proporcionar una presentación para inversores titulada “Producción de proteínas recombinantes de precisión que redefine el rendimiento, la escalabilidad y la economía.” La presentación, publicada en el sitio web de la empresa y adjunta como Exhibit 99.1, describe un cambio estratégico de operaciones centradas en la investigación a un enfoque comercial. La dirección planea monetizar sus plataformas de expresión génica patentadas C1 y Dapibus™ suministrando proteínas no terapéuticas de alto valor a los mercados de ciencias de la vida, alimentación, nutrición y bioprocesos industriales. No se divulgaron nuevos resultados financieros, pronósticos ni detalles transaccionales. Debido a que el material es “proporcionado” y no “presentado,” no está sujeto a la responsabilidad bajo la Sección 18 y no se incorporará automáticamente en futuras presentaciones bajo la Ley de Valores o la Ley de Intercambio. El Exhibit 104 contiene los datos de la portada XBRL en línea.

Dyadic International (나스닥: DYAI)는 2025년 7월 23일 항목 7.01(Reg FD)에 따라 투자자 발표 자료를 제공하기 위해 Form 8-K를 제출했습니다. 발표 제목은 “성능, 확장성 및 경제성을 재정의하는 정밀 설계된 재조합 단백질 생산”입니다. 이 자료는 회사 웹사이트에 게시되었으며 Exhibit 99.1로 첨부되어 있습니다. 연구 중심에서 상업 중심 운영으로의 전략적 전환을 설명합니다. 경영진은 특허받은 C1 및 Dapibus™ 유전자 발현 플랫폼을 활용하여 생명과학, 식품, 영양 및 산업 생물공정 시장에 고부가가치 비치료용 단백질을 공급하여 수익화할 계획입니다. 새로운 재무 결과, 가이드라인 또는 거래 세부사항은 공개되지 않았습니다. 이 자료는 “제출”이 아닌 “제공”된 것이므로 섹션 18 책임 대상이 아니며 향후 증권법 또는 거래법 제출 서류에 자동으로 포함되지 않습니다. Exhibit 104에는 인라인 XBRL 표지 데이터가 포함되어 있습니다.

Dyadic International (Nasdaq : DYAI) a déposé un formulaire 8-K le 23 juillet 2025 en vertu de l'article 7.01 (Reg FD) pour fournir une présentation aux investisseurs intitulée « Production de protéines recombinantes de précision qui redéfinit la performance, l'évolutivité et l'économie. » Le document, publié sur le site Web de la société et joint en tant qu'Exhibit 99.1, décrit un changement stratégique passant d'opérations axées sur la recherche à une orientation commerciale. La direction prévoit de monétiser ses plateformes d'expression génique brevetées C1 et Dapibus™ en fournissant des protéines non thérapeutiques à forte valeur ajoutée aux marchés des sciences de la vie, de l'alimentation, de la nutrition et du biotraitement industriel. Aucun nouveau résultat financier, prévision ou détail transactionnel n'a été divulgué. Étant donné que le document est « fourni » et non « déposé », il n'est pas soumis à la responsabilité en vertu de la section 18 et ne sera pas automatiquement intégré dans les futurs dépôts en vertu du Securities Act ou de l'Exchange Act. L'Exhibit 104 contient les données de la page de couverture XBRL en ligne.

Dyadic International (Nasdaq: DYAI) reichte am 23. Juli 2025 ein Formular 8-K unter Punkt 7.01 (Reg FD) ein, um eine Investorenpräsentation mit dem Titel „Präzise entwickelte rekombinante Proteinproduktion, die Leistung, Skalierbarkeit und Wirtschaftlichkeit neu definiert“ bereitzustellen. Die Präsentation, die auf der Unternehmenswebsite veröffentlicht und als Exhibit 99.1 beigefügt ist, skizziert eine strategische Verlagerung von forschungsorientierten zu kommerziell fokussierten Aktivitäten. Das Management plant, seine patentierten C1- und Dapibus™-Genexpressionsplattformen zu monetarisieren, indem es hochwertige, nicht-therapeutische Proteine für die Märkte der Lebenswissenschaften, Lebensmittel, Ernährung und industrielle Bioprozessierung liefert. Es wurden keine neuen Finanzergebnisse, Prognosen oder Transaktionsdetails bekannt gegeben. Da das Material „bereitgestellt“ und nicht „eingereicht“ wurde, unterliegt es nicht der Haftung nach Abschnitt 18 und wird nicht automatisch in zukünftige Einreichungen nach dem Securities Act oder Exchange Act aufgenommen. Exhibit 104 enthält die Inline-XBRL-Titelseitendaten.

Positive
  • Strategic pivot to commercialization may unlock new revenue streams across multiple end-markets.
  • Emphasis on proprietary C1 and Dapibus™ platforms reinforces technological differentiation.
Negative
  • No financial metrics, contracts or timelines were provided to gauge revenue impact.
  • Information classified as “furnished” limits investor protections and may reduce disclosure rigor.

Insights

TL;DR: Informational 8-K; outlines commercial focus but lacks financial metrics—impact neutral.

The filing merely furnishes an investor deck, so there is no legally binding disclosure of revenues, margins or forecasts. While the move from R&D to commercialization could expand addressable markets and improve cash-flow visibility, the absence of quantified targets or customer agreements prevents valuation adjustments at this stage. Because the information is not “filed,” investors receive limited recourse if projections prove optimistic. I therefore view the event as not immediately price-moving, pending concrete revenue evidence.

TL;DR: Highlighted C1/Dapibus platforms show technical edge; market uptake still unproven.

Dyadic continues to market its fungal C1 and plant-based Dapibus™ expression systems as faster and cheaper than CHO or microbial alternatives. Positioning toward food and industrial enzymes diversifies risk away from competitive therapeutic biologics. However, without announced manufacturing partnerships, regulatory clearances, or pilot-scale data, the commercial roadmap remains theoretical. Overall, the disclosure confirms strategic intent but offers little new operational substance.

Dyadic International (Nasdaq: DYAI) ha presentato un modulo 8-K il 23 luglio 2025 ai sensi dell'Elemento 7.01 (Reg FD) per fornire una presentazione agli investitori intitolata “Produzione di proteine ricombinanti di precisione che ridefinisce prestazioni, scalabilità ed economia.” La presentazione, pubblicata sul sito web dell'azienda e allegata come Exhibit 99.1, illustra un cambiamento strategico da un'operatività orientata alla ricerca a una focalizzata sul commerciale. Il management prevede di monetizzare le sue piattaforme brevettate di espressione genica C1 e Dapibus™ fornendo proteine non terapeutiche ad alto valore ai mercati delle scienze della vita, alimentare, nutrizionale e del bioprocesso industriale. Non sono stati divulgati nuovi risultati finanziari, previsioni o dettagli transazionali. Poiché il materiale è “fornito” e non “depositato,” non è soggetto alla responsabilità ai sensi della Sezione 18 e non sarà automaticamente incorporato nelle future dichiarazioni ai sensi del Securities Act o dell'Exchange Act. L'Exhibit 104 contiene i dati della pagina di copertina XBRL in linea.

Dyadic International (Nasdaq: DYAI) presentó un Formulario 8-K el 23 de julio de 2025 bajo el Ítem 7.01 (Reg FD) para proporcionar una presentación para inversores titulada “Producción de proteínas recombinantes de precisión que redefine el rendimiento, la escalabilidad y la economía.” La presentación, publicada en el sitio web de la empresa y adjunta como Exhibit 99.1, describe un cambio estratégico de operaciones centradas en la investigación a un enfoque comercial. La dirección planea monetizar sus plataformas de expresión génica patentadas C1 y Dapibus™ suministrando proteínas no terapéuticas de alto valor a los mercados de ciencias de la vida, alimentación, nutrición y bioprocesos industriales. No se divulgaron nuevos resultados financieros, pronósticos ni detalles transaccionales. Debido a que el material es “proporcionado” y no “presentado,” no está sujeto a la responsabilidad bajo la Sección 18 y no se incorporará automáticamente en futuras presentaciones bajo la Ley de Valores o la Ley de Intercambio. El Exhibit 104 contiene los datos de la portada XBRL en línea.

Dyadic International (나스닥: DYAI)는 2025년 7월 23일 항목 7.01(Reg FD)에 따라 투자자 발표 자료를 제공하기 위해 Form 8-K를 제출했습니다. 발표 제목은 “성능, 확장성 및 경제성을 재정의하는 정밀 설계된 재조합 단백질 생산”입니다. 이 자료는 회사 웹사이트에 게시되었으며 Exhibit 99.1로 첨부되어 있습니다. 연구 중심에서 상업 중심 운영으로의 전략적 전환을 설명합니다. 경영진은 특허받은 C1 및 Dapibus™ 유전자 발현 플랫폼을 활용하여 생명과학, 식품, 영양 및 산업 생물공정 시장에 고부가가치 비치료용 단백질을 공급하여 수익화할 계획입니다. 새로운 재무 결과, 가이드라인 또는 거래 세부사항은 공개되지 않았습니다. 이 자료는 “제출”이 아닌 “제공”된 것이므로 섹션 18 책임 대상이 아니며 향후 증권법 또는 거래법 제출 서류에 자동으로 포함되지 않습니다. Exhibit 104에는 인라인 XBRL 표지 데이터가 포함되어 있습니다.

Dyadic International (Nasdaq : DYAI) a déposé un formulaire 8-K le 23 juillet 2025 en vertu de l'article 7.01 (Reg FD) pour fournir une présentation aux investisseurs intitulée « Production de protéines recombinantes de précision qui redéfinit la performance, l'évolutivité et l'économie. » Le document, publié sur le site Web de la société et joint en tant qu'Exhibit 99.1, décrit un changement stratégique passant d'opérations axées sur la recherche à une orientation commerciale. La direction prévoit de monétiser ses plateformes d'expression génique brevetées C1 et Dapibus™ en fournissant des protéines non thérapeutiques à forte valeur ajoutée aux marchés des sciences de la vie, de l'alimentation, de la nutrition et du biotraitement industriel. Aucun nouveau résultat financier, prévision ou détail transactionnel n'a été divulgué. Étant donné que le document est « fourni » et non « déposé », il n'est pas soumis à la responsabilité en vertu de la section 18 et ne sera pas automatiquement intégré dans les futurs dépôts en vertu du Securities Act ou de l'Exchange Act. L'Exhibit 104 contient les données de la page de couverture XBRL en ligne.

Dyadic International (Nasdaq: DYAI) reichte am 23. Juli 2025 ein Formular 8-K unter Punkt 7.01 (Reg FD) ein, um eine Investorenpräsentation mit dem Titel „Präzise entwickelte rekombinante Proteinproduktion, die Leistung, Skalierbarkeit und Wirtschaftlichkeit neu definiert“ bereitzustellen. Die Präsentation, die auf der Unternehmenswebsite veröffentlicht und als Exhibit 99.1 beigefügt ist, skizziert eine strategische Verlagerung von forschungsorientierten zu kommerziell fokussierten Aktivitäten. Das Management plant, seine patentierten C1- und Dapibus™-Genexpressionsplattformen zu monetarisieren, indem es hochwertige, nicht-therapeutische Proteine für die Märkte der Lebenswissenschaften, Lebensmittel, Ernährung und industrielle Bioprozessierung liefert. Es wurden keine neuen Finanzergebnisse, Prognosen oder Transaktionsdetails bekannt gegeben. Da das Material „bereitgestellt“ und nicht „eingereicht“ wurde, unterliegt es nicht der Haftung nach Abschnitt 18 und wird nicht automatisch in zukünftige Einreichungen nach dem Securities Act oder Exchange Act aufgenommen. Exhibit 104 enthält die Inline-XBRL-Titelseitendaten.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person*
Cheng Chi Fung

(Last) (First) (Middle)
110 RIO ROBLES

(Street)
SAN JOSE CA 95134

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Credo Technology Group Holding Ltd [ CRDO ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Technology Officer
3. Date of Earliest Transaction (Month/Day/Year)
07/21/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Ordinary Shares 07/21/2025 S(1) 2,200 D $94.0933(2) 7,271,761 I Cheng Huang Family Trust(3)
Ordinary Shares 07/21/2025 S(1) 7,870 D $95.1924(4) 7,263,891 I Cheng Huang Family Trust(3)
Ordinary Shares 07/21/2025 S(1) 15,202 D $96.1277(5) 7,248,689 I Cheng Huang Family Trust(3)
Ordinary Shares 07/21/2025 S(1) 24,510 D $97.1335(6) 7,224,179 I Cheng Huang Family Trust(3)
Ordinary Shares 07/21/2025 S(1) 5,218 D $97.9848(7) 7,218,961 I Cheng Huang Family Trust(3)
Ordinary Shares 116,890 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Cheng Huang Family Trust on September 6, 2024.
2. This transaction was executed in multiple trades at prices ranging from $93.59 to $94.53. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
3. Represents ordinary shares held by the Cheng Huang Family Trust of which the Reporting Person and his spouse are trustees and the Reporting Person, his spouse and their children are beneficiaries. The Reporting Person disclaims beneficial ownership except to the extent of his and his spouse's pecuniary interest therein. The full name of the trust is the Cheng Huang Family Trust U/T/A DTD 12/22/2003.
4. This transaction was executed in multiple trades at prices ranging from $94.60 to $95.58. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
5. This transaction was executed in multiple trades at prices ranging from $95.62 to $96.61. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
6. This transaction was executed in multiple trades at prices ranging from $96.62 to $97.61. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
7. This transaction was executed in multiple trades at prices ranging from $97.62 to $98.42. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Remarks:
/s/ James Laufman, attorney-in-fact 07/23/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Dyadic International (DYAI) disclose in its 8-K dated July 23 2025?

The company furnished an investor presentation detailing its shift toward commercializing proteins via its C1 and Dapibus™ platforms.

Does the 8-K include updated financial results or guidance for DYAI?

No. No revenue, earnings, or guidance figures were included in the filing.

Why is the presentation classified as “furnished” and not “filed”?

Items furnished under Reg FD avoid Section 18 liability and are not automatically incorporated into other SEC filings.

What markets does Dyadic plan to target with its C1 and Dapibus™ platforms?

Management highlighted life-science, food, nutrition and industrial bioprocessing applications.

Where can investors access the full Dyadic presentation?

The deck is available at www.dyadic.com under the “Investors” tab and as Exhibit 99.1 to the 8-K.
CREDO TECHNOLOGY GROUP HOLDING

NASDAQ:CRDO

CRDO Rankings

CRDO Latest News

CRDO Latest SEC Filings

CRDO Stock Data

15.95B
146.86M
15.15%
76.03%
5.19%
Semiconductors
Semiconductors & Related Devices
Link
Cayman Islands
GRAND CAYMAN